DrugsDisclosed.com Launches ‘Medication Trustpilot’ to Amplify Patient Voices
Review platform launches in light of new research which reveals that 93% lack trust in pharma companies.
DrugsDisclosed.com launched today to give patients more control over their own treatments to share real world experiences of their medicines. Alongside today’s launch, new research underlines the need for pharmaceutical companies to better listen and learn from these experiences — with a ‘trust deficit’ opening up between patients and the industry that develops and produces their medicines.
DrugsDisclosed.com is a review platform that offers patients the chance to quickly share and compare their experiences with others using the same medications. The site collates data from over 352,044 unique patient medication reviews from the associated DrugStars medication management app.
Trust deficit
The need for patients to be heard is confirmed in research commissioned by DrugsDisclosed.com and market research partner Userneeds. Results reveal that patients feel ignored once medicines go to market and regard pharmaceutical companies with suspicion. The survey of more than a thousand users of prescription and over the counter (OTC) medicines from the UK and Ireland revealed:
- 93% of patients do not trust advice from pharmaceutical companies about their medication
- 84% feel the pharmaceutical industry influences prescription decisions
- 68% expressed a desire to be able to feedback their experiences to pharma companies
- 81% of patients do not feel listened to by pharmaceutical companies
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
